{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T06:52:56Z","timestamp":1773730376700,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T00:00:00Z","timestamp":1666742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007771","name":"\u015al\u0105ski Uniwersytet Medyczny","doi-asserted-by":"publisher","award":["KNW-2-K32\/D\/6\/N"],"award-info":[{"award-number":["KNW-2-K32\/D\/6\/N"]}],"id":[{"id":"10.13039\/100007771","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Doc Ophthalmol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Neurotoxicity, including optic nerve injury, is one of the most common adverse effects of tacrolimus, the principal calcineurin inhibitor used after kidney transplantation (KTx). The electrophysiologic measurements of both pattern visual evoked potentials (PVEP) and flash visual evoked potentials (FVEP) are valuable when drug-induced optic neuropathy is suspected.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>To determine whether VEP measurement is a sensitive and repeatable method for monitoring tacrolimus neurotoxicity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Material and methods<\/jats:title>\n                <jats:p>This prospective study focused on 35 patients (20\u00a0M, 15F, 69 eyes, mean age 43\u2009\u00b1\u200911\u00a0years) who were at a median of 3.0 (IQR, 2.2\u20133.7) months after KTx at the time of the initial VEP evaluation and were treated with tacrolimus since KTx. The follow-up VEP examination was done after a median of 24 (22\u201327) months (both VEP measurements followed the ISCEV standards). The P100 wave latency and amplitude for the 1\u00b0 and 15\u2019 PVEP simulations, and the P2 wave latency and amplitude for the FVEP were analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>For the 1\u00b0 checks, the P100 wave latency and amplitude values were significantly worse in the follow-up examination compared to the early post-transplant time-point. Independent associations between FVEP parameters and the tacrolimus blood trough level were observed in the follow-up examination but not at the early post-transplant period. The P2 wave latency correlated with the tacrolimus trough level only in patients treated with the twice-daily, but not the once-daily, tacrolimus formulation. The brain derived neurotrophic factor (BDNF) level correlated with the P100 (15\u2019) latency (<jats:italic>R<\/jats:italic>\u2009=\u20090.499; <jats:italic>p<\/jats:italic>\u2009=\u20090.005) and the P2 latency (<jats:italic>R<\/jats:italic>\u2009=\u20090.409; <jats:italic>p<\/jats:italic>\u2009=\u20090.025) only in patients treated with the once-daily, but not the twice-daily, tacrolimus formulation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The observations in this study may support the rationale for the use of VEP measurements as non-invasive monitoring of subclinical tacrolimus neurotoxicity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10633-022-09898-4","type":"journal-article","created":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T13:07:41Z","timestamp":1666789661000},"page":"197-209","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Visual evoked potentials as a method for the prospective assessment of tacrolimus neurotoxicity in patients after kidney transplantation"],"prefix":"10.1007","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3138-3011","authenticated-orcid":false,"given":"Sebastian","family":"Sirek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aureliusz","family":"Kolonko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dorota","family":"Pojda-Wilczek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,26]]},"reference":[{"key":"9898_CR1","unstructured":"Kr\u00f3l E, Rutkowski B: Przewlek\u0142a choroba nerek\u2014klasyfikacja, epidemiologia"},{"key":"9898_CR2","unstructured":"i diagnostyka. Forum Nefrol., 2008; 1: 1\u20136."},{"key":"9898_CR3","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1056\/NEJM199912023412303","volume":"341","author":"RA Wolfe","year":"1999","unstructured":"Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LYC et al (1999) Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 341:1725\u20131730","journal-title":"N Engl J Med"},{"key":"9898_CR4","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/0167-5699(92)90111-J","volume":"13","author":"SL Schreiber","year":"1992","unstructured":"Schreiber SL, Crabtree GR (1992) The mechanism of action of cyclosporin A and FK506. Immunol Today 13:136","journal-title":"Immunol Today"},{"key":"9898_CR5","first-page":"1","volume":"1","author":"BM Shrestha","year":"2017","unstructured":"Shrestha BM (2017) Two decades of tacrolimus in renal transplant: Basic science and clinical evidences. Exp Clin Transpl 1:1\u20139","journal-title":"Exp Clin Transpl"},{"key":"9898_CR6","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1097\/00007890-199405820-00006","volume":"58","author":"AR Mueller","year":"1994","unstructured":"Mueller AR, Platz K-P, Bechstein W-O, Schattenfroh N, Stoltenburg-Didinger G, Blumhardt G et al (1994) Neurotoxicity after orthotopic liver transplantation. Transplantation 58:155\u2013169","journal-title":"Transplantation"},{"key":"9898_CR7","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1111\/tri.12850","volume":"29","author":"VR Dharnidharka","year":"2016","unstructured":"Dharnidharka VR, Schnitzler MA, Chen J, Brennan DC, Axelrod D, Segev DL, Lentine KL, Schechtman KB, Zheng J (2016) Differential risks for adverse outcomes 3 years after kidney transplantation based on initial immunosuppression regimen: a national study. Transpl Int 29:1226\u20131236","journal-title":"Transpl Int"},{"issue":"937","key":"9898_CR8","first-page":"942","volume":"7","author":"EF Wijdicks","year":"2001","unstructured":"Wijdicks EF (2001) Neurotoxicity of immunosuppressive drugs. Liver Transpl 7(937):942","journal-title":"Liver Transpl"},{"key":"9898_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clineuro.2004.07.012","volume":"107","author":"R Brouns","year":"2004","unstructured":"Brouns R, De Deyn PP (2004) Neurological complications in renal failure: a review. Clin Neurol Neurosurg 107:1\u201316","journal-title":"Clin Neurol Neurosurg"},{"key":"9898_CR10","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1136\/jnnp.51.11.1434","volume":"51","author":"RJ Lane","year":"1988","unstructured":"Lane RJ, Roche SW, Leung AA, Greco A, Lange LS (1988) Cyclosporine neurotoxicity in cardiac transplant recipients. J Neurol Neurosurg Psychiatry 51:1434\u20131437","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"9898_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.trre.2006.02.005","volume":"20","author":"TC Tan","year":"2006","unstructured":"Tan TC, Robinson PJ (2006) Mechanisms of calcineurin inhibitor-induced neurotoxicity. Transpl Rev 20:49\u201360","journal-title":"Transpl Rev"},{"key":"9898_CR12","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2214\/ajr.166.3.8623651","volume":"166","author":"BA Appignani","year":"1996","unstructured":"Appignani BA, Bhadelia RA, Blacklow SC, Wang AK, Roland SF, Freeman RB (1996) Neuroimaging findings in patients on immunosuppressive therapy: Experience with tacrolimus toxicity. Am J Roentgenol 166:683\u2013688","journal-title":"Am J Roentgenol"},{"key":"9898_CR13","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1053\/j.ackd.2019.08.006","volume":"27","author":"SS Farouk","year":"2020","unstructured":"Farouk SS, Rein JL (2020) The many faces of calcineurin inhibitor toxicity\u2014What the FK? Adv Chronic Kidney Dis 27:56\u201366","journal-title":"Adv Chronic Kidney Dis"},{"key":"9898_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1159\/000445896","volume":"98","author":"X-X Liu","year":"2016","unstructured":"Liu X-X, Xu B-M, Chen H, Song Y-Y, Yang W-H, Chen B (2016) Limited sampling strategy for the estimation of tacrolimus area under the concentration-time curve in Chinese adult liver transplant patients. Pharmacology 98:229\u2013241","journal-title":"Pharmacology"},{"issue":"1","key":"9898_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10633-016-9553-y","volume":"133","author":"JV Odom","year":"2016","unstructured":"Odom JV, Bach M, Brigell M, Holder GE, McCulloch DLL, Mizota A, Tormene AP (2016) International Society for Clinical Electrophysiology of Vision: ISCEV standard for clinical visual evoked potentials \u2013 (2016 update). Doc Ophthalmol 133(1):1\u20139","journal-title":"Doc Ophthalmol"},{"issue":"2426","key":"9898_CR16","first-page":"2432","volume":"13","author":"R Arnold","year":"2013","unstructured":"Arnold R, Pussell BA, Pianta TJ, Lin CS, Kiernan MC (2013) Krish\u00acnan AV: Association between calcineurin inhibitor treatment and peripheral nerve dysfunction in renal transplant recipients. Am J Transplant 13(2426):2432","journal-title":"Am J Transplant"},{"key":"9898_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/0013-4694(87)90179-9","volume":"66","author":"JJ Brown","year":"1987","unstructured":"Brown JJ, Sufit RL, Sollinger HW (1987) Visual evoked potential changes following renal transplantation. Electroencephalogr Clin Neurophysiol 66:101\u2013107","journal-title":"Electroencephalogr Clin Neurophysiol"},{"key":"9898_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.5604\/01.3001.0010.3787","volume":"71","author":"M Jurys","year":"2017","unstructured":"Jurys M, Sirek S, Kolonko A, Pojda-Wilczek D (2017) Visual evoked potentials in diagnostics of optic neuropathy associated with renal failure. Postepy Hig Med Dosw 71:32\u201339","journal-title":"Postepy Hig Med Dosw"},{"key":"9898_CR19","doi-asserted-by":"crossref","unstructured":"Derici U, Nazliel B, Irkec C, Sindel S, Arinsoy T, Bali M: Effect of haemodialysis on visual evoked potential parameters. Nephro\u00aclogy, 2003; 8: 11 15.","DOI":"10.1046\/j.1440-1797.2003.00135.x"},{"key":"9898_CR20","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/0013-4694(78)90268-7","volume":"44","author":"EG Lewis","year":"1978","unstructured":"Lewis EG, Dustman RE, Beck EC (1978) Visual and somatosensory evoked potential characteristics of patients undergoing hemodialysis and kidney transplantation. Electroencephalogr Clin Neurophysiol 44:223\u2013231","journal-title":"Electroencephalogr Clin Neurophysiol"},{"key":"9898_CR21","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.1016\/j.transproceed.2010.09.064","volume":"42","author":"M Talebi","year":"2010","unstructured":"Talebi M, Sayadnasiri M, Azar SA (2010) Effect of renal transplantation on visual evoked potential abnormalities of chronic renal failure. Transplant Proc 42:3994\u20133997","journal-title":"Transplant Proc"},{"key":"9898_CR22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3109\/15569527.2011.629325","volume":"31","author":"FJ Ascaso","year":"2012","unstructured":"Ascaso FJ, Mateo J, Huerva V, Cristobal JA (2012) Unilateral tacrolimus-associated optic neuropathy after liver transplantation. Cutan Ocul Toxicol 31:167\u2013170","journal-title":"Cutan Ocul Toxicol"},{"key":"9898_CR23","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1111\/j.1399-3046.2008.00961.x","volume":"12","author":"O Al-Masri","year":"2008","unstructured":"Al-Masri O, Fathallah W, Quader S (2008) Recovery of tacrolimus-associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient \u2013 case report and review of the literature. Pediatr Transplant 12:914\u2013917","journal-title":"Pediatr Transplant"},{"key":"9898_CR24","first-page":"72","volume":"82","author":"PA Rizzo","year":"1982","unstructured":"Rizzo PA, Pierelli F, Pozzessere G, Verardi S, Casciani CU, Morocutti C (1982) Pattern visual evoked potentials and brainstem auditory evoked responses in uremic patiemts. Acta Neurol Belg 82:72\u201379","journal-title":"Acta Neurol Belg"},{"key":"9898_CR25","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1001\/archneur.1983.04050090081014","volume":"40","author":"C Tiannikas","year":"1983","unstructured":"Tiannikas C, Walsh JC, McLeod JG (1983) Visual evoked potentials in the detection of subclinical optic nerve effects secondary to ethambutol. Arch Neurol 40:645\u2013648","journal-title":"Arch Neurol"},{"key":"9898_CR26","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1136\/bjo.2008.148502","volume":"93","author":"V Menon","year":"2009","unstructured":"Menon V, Jain D, Saxena R, Sood R (2009) Prospective evaluation of visual function for early detection of ethambutol toxicity. Br J Ophthalmol 93:1251\u20131254","journal-title":"Br J Ophthalmol"},{"key":"9898_CR27","unstructured":"Fahle M, Bach M (2006) Origin of the Visual Evoked Potentials. In: Principles and practice of clinical electrophysiology of vision. Second edition. Ed. Heckenlively JR and Arden GB. The Mit Press Cambridge, Massachusetts London, England, p 220"},{"issue":"6","key":"9898_CR28","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.3390\/jcm9061827","volume":"9","author":"A Kolonko","year":"2020","unstructured":"Kolonko A, Jurys M, Sirek S, Dwulit T, Pojda-Wilczek D, Wi\u0119cek A (2020) The effect of maintenance treatment with twice-daily or prolonged once-daily tacrolimus formulation on visual evoked potentials in stable kidney transplant recipients. J Clin Med 9(6):1827. https:\/\/doi.org\/10.3390\/jcm9061827","journal-title":"J Clin Med"},{"key":"9898_CR29","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1111\/tri.12435","volume":"27","author":"JS Zaltzman","year":"2014","unstructured":"Zaltzman JS, Lai V, Schulz MZ, Moon KH, Cherney DZ (2014) A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers. Transpl Int 27:1294\u20131302","journal-title":"Transpl Int"},{"key":"9898_CR30","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/ctr.12581","volume":"29","author":"A Langone","year":"2015","unstructured":"Langone A, Steinberg SM, Gedaly R, Chan LK, Shah T, Sethi KD, Nigro V, Morgan JC, Formica RN, Barr YM (2015) Switching study of kidney transplant patients with tremor to LCP-Tacro (STRATO): an open-label, multicenter, prospective phase 3b study. Clin Transpl 29:796\u2013805","journal-title":"Clin Transpl"},{"key":"9898_CR31","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1159\/000514441","volume":"64","author":"E Fudalej","year":"2021","unstructured":"Fudalej E, Justyniarska M, Kasare\u0142\u0142o K, Dziedziak J, Szaflik JP, Cudnoch-J\u0119drzejewska A (2021) Neuroprotective factor of the retina and their role in promoting survival of retinal ganglion cells: a review. Ophthalmic Res 64:345\u2013355","journal-title":"Ophthalmic Res"},{"key":"9898_CR32","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.cellbi.2009.04.006","volume":"33","author":"B Gabryel","year":"2009","unstructured":"Gabryel B, Bernacki J (2009) Effects of FK506 and cyclosporine A on the expression of BDNF, tyrosine kinase B and p75 neurotrophin receptors in astrocytes exposed to simulated ischemia in vitro. Cell Biol Int 33:739\u2013748","journal-title":"Cell Biol Int"},{"key":"9898_CR33","doi-asserted-by":"crossref","unstructured":"Shin YJ, Chun YT, Lim SW, Luo K, Quan Yi, Cui S et al. (2019) Influence of tacrolimus on depressive-like behavior in diabetic rats through brain-derived neurotrophic factor regulation in the hippocampus. Neurotox Res 36:396\u2013410","DOI":"10.1007\/s12640-019-00062-6"},{"key":"9898_CR34","doi-asserted-by":"crossref","unstructured":"Walsh P, Kane N, Butler S (2005) The clinical role of evoked potentials. J Neurol Neurosurg Psychiatry 76 Suppl II:16\u201322","DOI":"10.1136\/jnnp.2005.068130"}],"container-title":["Documenta Ophthalmologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10633-022-09898-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10633-022-09898-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10633-022-09898-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T07:11:40Z","timestamp":1668237100000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10633-022-09898-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,26]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["9898"],"URL":"https:\/\/doi.org\/10.1007\/s10633-022-09898-4","relation":{},"ISSN":["0012-4486","1573-2622"],"issn-type":[{"value":"0012-4486","type":"print"},{"value":"1573-2622","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,26]]},"assertion":[{"value":"3 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in the study were in accordance with the ethical standards of the Medical University of Silesia in Katowice Bioethical Commission (agreement \u2013 no. KNW\/0022\/KB1\/93\/13) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of Human Rights"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Patients signed informed consent regarding publishing their data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare they have no financial interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial interests"}}]}}